1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.26%
Cash & equivalents declining -13.26% while Drug Manufacturers - Specialty & Generic shows -1.85% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-5.82%
Cash + STI yoy growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.51%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-12.67%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-15.83%
Inventory growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
No Data
No Data available this quarter, please select a different quarter.
-6.90%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -0.71%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-21.57%
PP&E growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.51%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
-23.49%
Goodwill growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for future write-down risk or pricey takeovers.
-18.15%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -1.68%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-21.80%
Exceeding 1.5x Drug Manufacturers - Specialty & Generic median of -1.57%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-4.60%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
No Data
No Data available this quarter, please select a different quarter.
-33.35%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.27%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-22.37%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.23%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-20.07%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of -1.37%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-11.44%
Payables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
28.78%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
188.78%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
No Data
No Data available this quarter, please select a different quarter.
-39.61%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
10.12%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.98%. Jim Chanos suspects potential working capital strain.
-16.76%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
-8.71%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
7430.27%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-11.56%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -2.59%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-2.23%
Above 1.5x Drug Manufacturers - Specialty & Generic median of -0.86%. Jim Chanos suspects an alarming rise in overall leverage.
1.64%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-105.90%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.05%. Joel Greenblatt sees stronger retained profit growth vs. peers.
64.64%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-23.86%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -0.54%. Joel Greenblatt sees stronger equity growth vs. peers.
-20.07%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of -1.37%. Joel Greenblatt sees more aggressive expansions than peers.
-0.23%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-0.85%
Near Drug Manufacturers - Specialty & Generic median of -0.82%. Charlie Munger sees typical overall debt changes in the sector.
4.79%
Above 1.5x Drug Manufacturers - Specialty & Generic median 0.55%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.
